These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2988431)

  • 1. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.
    Ninomiya Y; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Antimicrob Agents Chemother; 1985 Apr; 27(4):595-9. PubMed ID: 2988431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of drug resistance to new antirhinovirus agents.
    Ishitsuka H; Ninomiya Y; Suhara Y
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.
    Ahmad AL; Tyrrell DA
    Antiviral Res; 1986 Jul; 6(4):241-52. PubMed ID: 3017203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of rhinovirus resistant to an antiviral chalcone.
    Ahmad AL; Dowsett AB; Tyrrell DA
    Antiviral Res; 1987 Aug; 8(1):27-39. PubMed ID: 2825590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.
    Ishitsuka H; Ninomiya YT; Ohsawa C; Fujiu M; Suhara Y
    Antimicrob Agents Chemother; 1982 Oct; 22(4):617-21. PubMed ID: 6295261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 'new' generation of more potent synthetic antirhinovirus compounds: comparison of their MICs and their synergistic interactions.
    Al-Nakib W; Tyrrell DA
    Antiviral Res; 1987 Nov; 8(4):179-87. PubMed ID: 2833156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B.
    Tisdale M; Selway JW
    J Antimicrob Chemother; 1984 Aug; 14 Suppl A():97-105. PubMed ID: 6092321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
    Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
    Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
    Dewindt B; van Eemeren K; Andries K
    Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of an early stage of rhinovirus replication by dichloroflavan (BW683C).
    Tisdale M; Selway JW
    J Gen Virol; 1983 Apr; 64 (Pt 4)():795-803. PubMed ID: 6300302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RMI 15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone), a new antirhinovirus compound.
    Ash RJ; Parker RA; Hagan AC; Mayer GD
    Antimicrob Agents Chemother; 1979 Sep; 16(3):301-5. PubMed ID: 228594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes.
    Wyde PR; Six HR; Wilson SZ; Gilbert BE; Knight V
    Antimicrob Agents Chemother; 1988 Jun; 32(6):890-5. PubMed ID: 2843086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.
    Andries K; Dewindt B; Snoeks J; Willebrords R
    Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex.
    Brown-Augsburger P; Vance LM; Malcolm SK; Hsiung H; Smith DP; Heinz BA
    Arch Virol; 1999; 144(8):1569-85. PubMed ID: 10486111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.
    Yasin SR; al-Nakib W; Tyrrell DA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):963-6. PubMed ID: 2168152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistant rhinoviruses from the nose of experimentally treated volunteers.
    Dearden C; al-Nakib W; Andries K; Woestenborghs R; Tyrrell DA
    Arch Virol; 1989; 109(1-2):71-81. PubMed ID: 2558631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
    Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
    J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound.
    Verheyden B; Andries K; Rombaut B
    Antiviral Res; 2004 Mar; 61(3):189-94. PubMed ID: 15168800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.
    Heinz BA; Vance LM
    J Virol; 1995 Jul; 69(7):4189-97. PubMed ID: 7769678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.